In this article, we review the mechanisms and clinical benefits of SGLT2 inhibitors and GLP-1RA and outline the rationale for their sequential or combined use in people with type 2 diabetes (T2D). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.